A larger dose of dexamethasone (12 mg) appeared to be less effective than the standard dose (6 mg) for COVID-19 patients in India.
Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia—a post hoc evaluation of the COVID STEROID 2 trial
Go to source) However, it had significant //benefits for severe COVID-19 patients in Europe, said a team of international researchers from India, the UK and Denmark. The study was conducted in Europe and India to examine the effects of giving patients injectable 12 mg versus 6 mg of dexamethasone every day for a maximum of 10 days.
Comparison of Dexamethasone Dosages in COVID-19 Hospitalizations
About 1,000 adult patients hospitalized with COVID-19 and severe hypoxaemia were enrolled from 26 hospitals in Denmark, India, Sweden and Switzerland between August 2020 and May 2021. Patients were randomized 1:1 to dexamethasone 12 mg or 6 mg intravenously (IV) once daily for up to 10 days.
Covid Pandemic: How Parents can Help Kids Deal with Back-to-School Anxiety
Understanding the role of the covid pandemic on back-to-school anxiety and children''s mental health can help prepare parents deal with their child''s anxiety.
Understanding the role of the covid pandemic on back-to-school anxiety and children''s mental health can help prepare parents deal with their child''s anxiety.
‘In India, a higher dose of dexamethasone might have fewer beneficial effects for patients compared to those in Europe. #steroid #COVIDtreatment ’
On day 28, the higher-dose group's risk of death was 8.3 percent lower for patients in Europe, whereas there was essentially no difference (0.1 percent) in India.The mortality benefits continued to be reduced for patients enrolled in India on day 90 and day 180, fewer number of days alive without life support at day 90, and at 180 days. But reassuringly, there did not appear to be an increase in the occurrence of serious adverse reactions at day 28 in Indian patients compared to Europeans.
"Variations in patient characteristics, healthcare infrastructure, resource availability, and comorbidity profiles may be the cause of the regional disparities in treatment effects," said researchers including from the George Institute for Global Health, in the paper." The observed discrepancies could be explained by variables including different levels of healthcare-associated infections, a higher incidence of diabetes, and the use of other anti-inflammatory medications such IL-6 inhibitors," they added.
Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to ...
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to ...
- Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia—a post hoc evaluation of the COVID STEROID 2 trial - (https://linkinghub.elsevier.com/retrieve/pii/S2772368223001531)
Loss of Taste and Smell from COVID Improves Over Three Years
People with post-COVID condition and altered smell should take comfort in the steady three-year recovery of their sense of smell.
People with post-COVID condition and altered smell should take comfort in the steady three-year recovery of their sense of smell.
